CD8A and neoplasm: Future DC engineering strategies might include novel methods to enhance endogenous antigen presentation functions and thus more efficiently priming endogenous CD8+ T-cells to target tumor cell TSAs while reversing local immunosuppression within the tumor microenvironment (123).